Cart
0
Get 20% Free Customization In This Report
Buy this report from - $3456

Neurological Biomarkers Market for Alzheimers and Parkinsons Diseases - Global Opportunity Analysis and Industry Forecast, 2018-2025

LI_183555
Pages: 90
Jun 2018 | 875 Views
face gplus_n
Author's : Tanvi Sapatnekar, Garima Chandra & Suraj Sajeev
Tables: 22
Charts: 25
twit_n pr_n

Neurological Biomarkers Market Overview:

The Neurological Biomarkers Market for Alzheimer’s and Parkinson’s disease was valued at $3,958.5 million in 2017, and is expected to reach $8,579.9 million by 2025, registering a CAGR of 10.1% from 2018-2025. Neurodegenerative diseases such as Alzheimer’s and Parkinson’s are characterized by gradual loss of cognitive function, dementia, and problems with movements. Currently, research activities focused on biomarkers in the field of neurodegenerative diseases is significantly important, owing to surge in incidence of Alzheimer’s and Parkinson’s diseases worldwide.

The key factors that boost the growth of the neurological biomarkers market for Alzheimer’s and Parkinson’s diseases include increase in focus on developing cost-effective biomarker testing and rise in demand for noninvasive diagnostic techniques for Alzheimer’s and Parkinson’s. In addition, surge in adoption of neurological biomarkers in clinical trials supplement the market growth. However, implementation of stringent government regulations towards the approval of commercial use of biomarkers and emerging ethical issues regarding early diagnosis of Alzheimer’s and Parkinson’s diseases are expected to hamper the market growth. Conversely, rise in demand for personalized medicine is anticipated to offer profitable opportunities for the expansion of the market.

Region Segment Review of Neurological Biomarkers Market for Alzheimer’s Disease

Get more information on this report : Request Sample Pages

Neurodegenerative biomarkers for Alzheimer’s disease based on region is categorized into U.S., EU5, rest of Europe, China, Asia-Pacific, and rest of world (ROW). U.S. was the leading market in 2017, followed by Europe. The dominance of U.S. in the Alzheimer’s market is attributed to rise in patient population that suffers from this disease. For instance, Alzheimer’s disease (AD) affects five million Americans per year, and is the sixth leading cause of death in the U.S. However, Asia-Pacific is projected to emerge as a lucrative market in the future, due to the presence of large patient pool affected by Alzheimer's disease and surge in geriatric population. Moreover, increase in awareness towards Alzheimer's disease is projected to augment the growth of the market in ROW.

Region Segment Review of Neurological Biomarkers Market for Parkinson’s Disease

Get more information on this report : Request Sample Pages

Neurodegenerative biomarkers for Alzheimer’s disease based on region is categorized into U.S., EU5, rest of Europe, China, Asia-Pacific, and rest of world (ROW). U.S. was the leading market in 2017, and is expected to continue this trend throughout the forecast period. This is attributed to rise in expenditure on the management of Parkinson’s disease in the country. As of 2017, U.S. had a population of 326,506,644 individuals, and about 60,000 individuals are diagnosed with Parkinson’s diseases every year. Thus, significant prevalence of this disease among the U.S. population drives the growth of the market. However, China is projected to emerge as a lucrative market in future, due to the higher prevalence of Parkinson’s disease observed in males in 2017.

The report provides a comprehensive analysis of the key players operating in the neurological biomarkers market for Alzheimer’s and Parkinson’s disease such as Abbott Laboratories, Myriad RBM, Proteome Sciences, Thermo Fisher Scientific, Athena Diagnostics, Immunarray Pvt. Ltd., Quanterix Corporation, Diagenic ASA, Psynova Neurotech, and Bio-Rad Laboratories.

Key Benefits for Stakeholders

  • The study provides an in-depth analysis with the current trends and future estimations of the neurological biomarkers market for Alzheimer’s and Parkinson’s diseases.
  • Comprehensive analysis of the factors that drive and restrict the market growth is provided.
  • The quantitative analysis of the industry from 2017 to 2025 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of key regions is provided to understand the neurological biomarkers market for Alzheimer’s and Parkinson’s diseases.
  • Key players and their strategies are analyzed to understand the competitive outlook of the market.

Neurological Biomarkers Market Key Segments:

By Region

  • U.S.
  • EU5
  • Rest of Europe
  • China
  • Asia-Pacific
  • Row
 

Chapter: 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
1.4.4. Key assumptions
1.4.5. Key experts

Chapter: 2: EXECUTIVE SUMMARY

2.1. CXO perspective

Chapter: 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Top winning strategies
3.3. Overall Diagnostic Market Size

3.3.1. Total diagnostic market size by diagnostic techniques

3.4. Incidence, Mortality, Diagnosis Rate, Prevalence Rate and Treatment Rate for Alzheimer’s And Parkinson’s Disease

3.4.1. Incidence rate
3.4.2. Mortality
3.4.3. Diagnosis rate
3.4.4. Prevalence rate
3.4.5. Treatment rate

3.5. Porter’s five forces analysis
3.6. Market dynamics

3.6.1. Drivers

3.6.1.1. Increasing focus on developing cost-effective biomarker testing
3.6.1.2. Rising demand for non-invasive diagnostic techniques for Alzheimer’s and Parkinson’s
3.6.1.3. Increase in the adoption of neurological biomarkers in clinical trials

3.6.2. Restraints

3.6.2.1. Stringent government regulations
3.6.2.2. Emerging ethical issues regarding early diagnosis of Alzheimer’s and Parkinson’s

3.6.3. Opportunity

3.6.3.1. Rise in the demand for personalized medicine

Chapter: 4: ALZHEIMER'S DISEASE BIOMARKERS MARKET, BY REGION

4.1. Overview

4.1.1. Market size and forecast

4.2. U.S.

4.2.1. Key market trends and opportunities
4.2.2. Market size and forecast

4.3. EU5

4.3.1. Key market trends and opportunities
4.3.2. Market size and forecast

4.4. Rest of Europe

4.4.1. Key market trends and opportunities
4.4.2. Market size and forecast

4.5. China

4.5.1. Key market trends and opportunities
4.5.2. Market size and forecast

4.6. Asia-Pacific

4.6.1. Key market trends and opportunities
4.6.2. Market size and forecast

4.7. Rest of World (ROW)

4.7.1. Key market trends and opportunities
4.7.2. Market size and forecast

Chapter: 5: PARKINSON’S DISEASE BIOMARKERS MARKET, BY REGION

5.1. Overview

5.1.1. Market size and forecast

5.2. U.S.

5.2.1. Key market trends and opportunities
5.2.2. Market size and forecast

5.3. EU5

5.3.1. Key market trends and opportunities
5.3.2. Market size and forecast

5.4. Rest of Europe

5.4.1. Key market trends and opportunities
5.4.2. Market size and forecast

5.5. China

5.5.1. Key market trends and opportunities
5.5.2. Key market trends and opportunities
5.5.3. Market size and forecast

5.6. Asia-Pacific

5.6.1. Key market trends and opportunities
5.6.2. Market size and forecast

5.7. ROW

5.7.1. Key market trends and opportunities
5.7.2. Market size and forecast

LIST OF TABLES

TABLE 01. KEY EXPERTS, NEUROLOGICAL BIOMARKERS MARKET
TABLE 02. TOTAL DIAGNOSTIC ALZHEIMER'S MARKET, BY DIAGNOSTIC TECHNIQUES, 2017-2025 ($MILLION)
TABLE 03. TOTAL DIAGNOSTIC PARKINSON'S MARKET, BY DIAGNOSTIC TECHNIQUES, 2017-2025 ($MILLION)
TABLE 04. STATISTICS FOR ALZHEIMER'S IN U.S.
TABLE 05. STATISTICS FOR ALZHEIMER'S IN EU5
TABLE 06. STATISTICS FOR ALZHEIMER'S IN REST OF EUROPE
TABLE 07. STATISTICS FOR ALZHEIMER'S IN CHINA
TABLE 08. STATISTICS FOR ALZHEIMER'S IN ASIA-PACIFIC
TABLE 09. STATISTICS FOR ALZHEIMER'S IN REST OF WORLD
TABLE 10. STATISTICS FOR PARKINSON’S IN U.S.
TABLE 11. STATISTICS FOR PARKINSON’S IN EU5
TABLE 12. STATISTICS FOR PARKINSON’S IN REST OF EUROPE
TABLE 13. STATISTICS FOR PARKINSON’S IN CHINA
TABLE 14. STATISTICS FOR PARKINSON’S IN ASIA-PACIFIC
TABLE 15. STATISTICS FOR PARKINSON’S IN REST OF WORLD
TABLE 16. NEUROLOGICAL BIOMARKERS MARKET FOR ALZHEIMER’S, BY RGION, 2017-2025 ($MILLION)
TABLE 17. INDIVIDUALS DIAGNOSED WITH ALZHEIMER'S DISEASE IN EU5, 2012
TABLE 18. HUNGARY ALZHEIMER'S DISEASE PREVALENCE, BY AGE GROUP
TABLE 19. ESTIMATED COST INCURRED & NUMBER OF INDIVIDUALS WITH ALZHEIMER’S DISEASE IN THE ASIA-PACIFIC REGION
TABLE 20. PREVALENCE OF ALZHEIMER'S DEMENTIA IN LATIN AMERICA, 2013
TABLE 21. NEUROLOGICAL BIOMARKERS MARKET FOR PARKINSON’S, BY GEOGRAPHY, 2017-2025 ($MILLION)
TABLE 22. PREVALENCE OF PARKINSON’S DISEASE IN ASIA-PACIFIC REGION, 2017
TABLE 23. PREVALENCE OF PARKINSON’S DISEASE IN ASIA-PACIFIC REGION, 2017

LIST OF FIGURES

FIGURE 01. TOP WINNING STRATEGIES, BY YEAR, 2014-2018*
FIGURE 02. TOP WINNING STRATEGIES, 2014-2018* (%)
FIGURE 03. TOP WINNING STRATEGIES, BY COMPANY, 2014-2018*
FIGURE 04. DIAGNOSTIC MARKET SIZE FOR ALZHEIMER’S, 2017-2025 ($MILLION)
FIGURE 05. DIAGNOSTIC MARKET SIZE FOR PARKINSON'S, 2017-2025 ($MILLION)
FIGURE 06. HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 07. HIGH BARGAINING POWER OF BUYERS
FIGURE 08. MODERATE THREAT OF SUBSTITUTION
FIGURE 09. MODERATE THREAT OF NEW ENTRANT
FIGURE 10. MODERATE COMPETITIVE RIVALRY
FIGURE 11. DRIVERS, RESTRAINTS, AND OPPORTUNITY: NEUROLOGICAL BIOMARKERS MARKET FOR ALZHEIMER’S (AD) AND PARKINSON’S (PD) DISEASES
FIGURE 12. PROJECTED NUMBER OF INDIVIDUALS IN THE U.S. WITH ALZHEIMER’S, 2010 TO 2050
FIGURE 13. ALZHEIMER'S DISEASE BIOMARKERS MARKET IN U.S.
FIGURE 14. ALZHEIMER'S DISEASE BIOMARKERS MARKET IN EU5
FIGURE 15. ALZHEIMER'S DISEASE BIOMARKERS MARKET IN REST OF EUROPE
FIGURE 16. NUMBER OF INDIVIDUALS IN CHINA WITH ALZHEIMER’S, 1990 TO 2010
FIGURE 17. ALZHEIMER'S DISEASE BIOMARKERS MARKET IN CHINA
FIGURE 18. ALZHEIMER'S DISEASE BIOMARKERS MARKET IN ASIA-PACIFIC
FIGURE 19. ALZHEIMER'S DISEASE BIOMARKERS MARKET IN ROW
FIGURE 20. PARKINSON’S DISEASE BIOMARKERS MARKET IN U.S.
FIGURE 21. PARKINSON’S DISEASE BIOMARKERS MARKET IN EU5
FIGURE 22. PARKINSON’S DISEASE BIOMARKERS MARKET IN REST OF EUROPE
FIGURE 23. PARKINSON’S DISEASE BIOMARKERS MARKET IN CHINA
FIGURE 24. PARKINSON’S DISEASE BIOMARKERS MARKET IN ASIA-PACIFIC
FIGURE 25. PARKINSON’S DISEASE BIOMARKERS MARKET IN ROW

 

Biomarkers used for the patients suffering from neurodegenerative diseases enable the presymptomatic disease detection that further aids in offering valuable insights while monitoring the disease intensity in patients. The utilization of biomarkers is projected to witness a significant increase, owing to high demand for cost-effective and noninvasive diagnostic methods for detection of onset of the aforementioned diseases. Several market players are investing in the research activities pertaining to the development of neurological biomarkers. In addition, large population base aging 65 and above in the emerging economies is expected to fuel the demand for neurological biomarkers across the diagnosis as well as therapy of Alzheimer’s and Parkinson’s. Moreover, rise in government funding in the development of novel diagnostic and treatment solutions in the developed countries contributes to the significant application of neurological biomarkers across the aforementioned diseases.

Furthermore, significant developments regarding personalized medicines for the patients with Alzheimer’s and Parkinson’s are anticipated to offer lucrative opportunities for the expansion of the market. Initiatives taken by key market players and local market players to develop cost-effective biomarker testing solutions for the patients suffering from Alzheimer’s and Parkinson’s disease is anticipated to drive the market growth in the near future. In addition, rise in preference for noninvasive neurological biomarker testing among the patients suffering from neurodegenerative disorders is expected to fuel the market growth.

 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry

Request sample

OR

Purchase Full Report of
Neurological Biomarkers Market- Global Opportunity Analysis and Industry Forecast, 2018-2025

  • Online Only
  • $3456
  • Online cloud Access only
  • Restected Print, copy, paste,download
  • Read Only
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Data Pack
  • $3840
  • Restricted to one authorized users
  • One print only
  • Available in Excel
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Single User
  • $5370
  • Restricted to one authorized users
  • One print only
  • Available in PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Five User
  • $6450
  • Limited to 5 authorized users
  • Print Upto Five Copies
  • Available in PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Enterprice
    License/PDF

  • $8995
  • Unlimited within company/enterprise
  • Unlimited within company/enterprise
  • Available in PDF
  • 20% free customization (Pre-Sale)
  • Free quartery industry update
  • Free report update (Within 180 days)
  • Subscription Model Sign In

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Access reports on all emerging
market of Life Sciences on Knowledge Tree Platform
Free Demo